AZR Azora Therapeutics, Inc. (DE)
Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.62M | $3.23M | $1.27M | $1.95M | $8.40M |
| SG&A expense | $5.18M | $5.06M | $5.62M | $8.91M | $9.34M |
| Operating income | -$7.80M | -$8.28M | -$6.89M | -$10.86M | -$19.29M |
| Pretax income | -$7.98M | -$13.20M | -$7.00M | -$10.80M | -$19.52M |
| Income tax | — | — | — | -$502 | -$94,077 |
| Net income | -$7.98M | -$13.20M | -$5.12M | -$12.73M | -$19.42M |
| EPS (basic) | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 |
| EPS (diluted) | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 |
| Weighted avg. shares (diluted) | 668,630 | 194,059 | 1.42M | 1.00M | 18.59M |
| Balance sheet | |||||
| Cash & equivalents | $5.88M | $3.75M | $2.83M | $4.00M | $6.06M |
| Current assets | $6.18M | $4.06M | $3.20M | $4.78M | $6.46M |
| PP&E, net | — | — | — | $50,424 | $58,149 |
| Goodwill | — | — | — | $248,971 | $248,971 |
| Intangibles | $3,000 | $3,348 | $3,913 | $4,477 | $5,041 |
| Total assets | $6.67M | $5.04M | $4.74M | $5.73M | $7.47M |
| Current liabilities | $1.40M | $975,858 | $653,076 | $1.79M | $2.72M |
| Total liabilities | $1.40M | $975,858 | $653,076 | $2.46M | $3.97M |
| Shareholders' equity | $5.28M | $4.07M | $4.08M | $3.28M | $3.51M |
| Shares outstanding | 1.11M | 258,826 | 1.66M | 1.07M | 20.95M |
| Cash flow statement | |||||
| Operating cash flow | -$6.49M | -$6.92M | -$6.81M | -$11.19M | -$11.95M |
| Capital expenditure | — | — | — | — | $64,605 |
| Free cash flow | — | — | — | — | -$12.01M |
| Investing cash flow | $150,000 | — | $1.50M | — | -$34,016 |
| Financing cash flow | $8.47M | $7.85M | $4.13M | $9.13M | $13.64M |
| Stock-based compensation | $676,200 | $796,831 | $1.75M | $3.37M | $4.24M |
| Share buybacks | — | — | $1,661 | — | — |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.